Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis.

Torkildsen Ø, Brustad HK, Høgestøl EA, Alstadhaug KB, Bhan A, Flemmen HØ, Habbestad A, Høglund RAA, LeBlanc M, Lopen P, Lorentzen ÅR, Morsund ÅH, Lossius A, Lundby R, Nygaard GO, Rød BE, Simonsen CS, Steffensen L, Torgauten H, Piehl F, Wergeland S, Myhr KM, OVERLORD-MS Investigators

Open source

DOI: 10.1056/nejmoa2600993
Published: 2026 Jul 2
Container: The New England journal of medicine
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1056/nejmoa2600993,
  title = {Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis.},
  author = {Torkildsen Ø and Brustad HK and Høgestøl EA and Alstadhaug KB and Bhan A and Flemmen HØ and Habbestad A and Høglund RAA and LeBlanc M and Lopen P and Lorentzen ÅR and Morsund ÅH and Lossius A and Lundby R and Nygaard GO and Rød BE and Simonsen CS and Steffensen L and Torgauten H and Piehl F and Wergeland S and Myhr KM and OVERLORD-MS Investigators},
  year = {2026},
  journal = {The New England journal of medicine},
  doi = {10.1056/nejmoa2600993},
  url = {https://doi.org/10.1056/nejmoa2600993}
}

RIS

TY  - JOUR
TI  - Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis.
AU  - Torkildsen Ø
AU  - Brustad HK
AU  - Høgestøl EA
AU  - Alstadhaug KB
AU  - Bhan A
AU  - Flemmen HØ
AU  - Habbestad A
AU  - Høglund RAA
AU  - LeBlanc M
AU  - Lopen P
AU  - Lorentzen ÅR
AU  - Morsund ÅH
AU  - Lossius A
AU  - Lundby R
AU  - Nygaard GO
AU  - Rød BE
AU  - Simonsen CS
AU  - Steffensen L
AU  - Torgauten H
AU  - Piehl F
AU  - Wergeland S
AU  - Myhr KM
AU  - OVERLORD-MS Investigators
PY  - 2026
JO  - The New England journal of medicine
DO  - 10.1056/nejmoa2600993
UR  - https://doi.org/10.1056/nejmoa2600993
ER  -

APA

Ø, T., HK, B., EA, H., KB, A., A, B., HØ, F., A, H., RAA, H., M, L., P, L., ÅR, L., ÅH, M., A, L., R, L., GO, N., BE, R., CS, S., L, S., H, T., F, P., S, W., KM, M., & Investigators, O. (2026). Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis.. The New England journal of medicine. https://doi.org/10.1056/nejmoa2600993

Source records

pubmed · retrieved 2026-11-10T09:40:27.544Z